Roche Fuzeon Phase IV Commitments Include Pneumonia Incidence Study
Executive Summary
Roche's postmarketing commitments for Fuzeon include a study on the incidence of pneumonia in HIV patients treated with the antiretroviral
You may also be interested in...
Aptivus Labeling Should Note Added Efficacy With Fuzeon, Committee Says
Labeling for Boehringer Ingelheim's HIV therapy Aptivus should note that tipranavir is most efficacious when used in combination with certain HIV therapies, particularlyFuzeon, members of FDA's Antiviral Drugs Advisory Committee said May 19
Aptivus Labeling Should Note Added Efficacy With Fuzeon, Committee Says
Labeling for Boehringer Ingelheim's HIV therapy Aptivus should note that tipranavir is most efficacious when used in combination with certain HIV therapies, particularlyFuzeon, members of FDA's Antiviral Drugs Advisory Committee said May 19
HIV Treatment Guidelines Give Kaletra Timely Boost As Reyataz Launches
HHS' revised guidelines for HIV treatment give Abbott's Kaletra a timely endorsement as Bristol-Myers Squibb is launching its competing protease inhibitor Reyataz